You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Optimi Health Corp. established Optimi Australia Pty Ltd as a wholly owned distribution and business development subsidiary in Australia and appointed Adrian Jones as Director of Australian Operations.
Optimi Health Corp. completed an MDMA production batch for a proposed Canadian Phase 3 PTSD trial enrolling up to 100 participants, a MAPS Israel trial, and an Australian commercial export planned before the end of 2026; the Canadian trial is expected to begin in 2027.
Optimi Health Corp. will participate in the ThinkEquity Conference on October 15, 2026, at the Mandarin Oriental Hotel in New York City, presenting a corporate overview at 4:00 p.m. Eastern time and holding investor meetings.
Optimi Health Corp. appointed Melanie Pump to its Board of Directors on September 29, 2026. Leah Hodges resigned as Corporate Secretary, and Chief Executive Officer Dane Stevens was appointed to fill the role.
Optimi Health Corp. completed and quality released a 5mg naturally derived psilocybin capsule batch to supply a Health Canada-approved Phase 2 MDD trial and licensed Australian clinics treating treatment-resistant depression.
Optimi Health Corp. appointed Michael Blough, Ph.D. as Chief Clinical Development Officer to oversee its planned Phase 2 psilocybin trial in major depressive disorder and Phase 3 MDMA trial in PTSD.
